OncoPep, Inc. is focused on developing innovative immunotherapeutics aimed at preventing cancer progression, extending patient survival, and enhancing quality of life. The company is leveraging the expertise of renowned oncologists from the Dana-Farber Cancer Institute to create a pipeline of investigational cancer vaccines and cell therapies. Their lead candidate, PVX-410, is a multi-peptide therapeutic vaccine currently undergoing clinical trials for treating triple-negative breast cancer (TNBC) and smoldering multiple myeloma (SMM). This vaccine works by stimulating the patient's immune system, specifically targeting cytotoxic T lymphocytes (CTLs) to attack tumor-associated antigens, thereby enhancing the body's natural ability to combat cancer.

In addition to PVX-410, OncoPep is developing MTAA-420, an autologous multi-tumor antigen adoptive T cell therapy. This approach involves stimulating and expanding the patient's own T cells ex vivo to target a proprietary peptide pool associated with multiple myeloma and solid tumors. By infusing these activated T cells back into the patient, OncoPep aims to create a robust immune response against multiple tumor antigens, potentially reducing the risk of tumor escape that can occur with single-target therapies. The company is also exploring next-generation vaccine technologies and novel delivery methods to broaden the applicability of their treatments across various patient populations.

United States

Through targeting multiple tumor-associated antigens with an investigational multi-peptide vaccine and a multi-tumor antigen adoptive (MTAA) T cell therapy, OncoPep’s T cell focused technologies are designed to be used on their own or in combination with other immunotherapeutics.

Cancer

Hematologic Diseases

Skin Diseases

OncoPep, Inc.

Triple-negative breast cancer

PVX-410 +CPI (Pembrolizumab) + Chemo

Antibodies

Biologics

Vaccines

PVX-410+ CPI ( Durvalumab)

Multiple myeloma

PVX-410+IMiD (lenalidomide)

PVX-410+IMiD + HDAC inhibitor (Lenalidomide+ citarinostat)

PVX-024 (vaccine for HLA- 024 population)

MTAA-420 (Adoptive T-cell therapy)

Cell Therapies

Solid tumor/s

PVX-510 (2nd generation vaccine) +TBD

Massachusetts

Peptide Therapies

Therapeutic

OncoPep, Inc.

Company Details